A double-blind, randomized, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general practice

Primary Care Psychiatry

Volumn 3, Issue 1, 1997, Pages 51-58

  Tylee, A ^a   Beaumont, G ^b   Bowden, M W ^c   Reynolds, A ^c  

^a Stonecot Surgery   (United Kingdom)

^b MGB Clinical and Drug Research   (United Kingdom)

^c PFIZER INC   (United States)

Author keywords

Clinical trial; Fluoxetine; Major depression; Primary care treatment; Venlafaxine

Indexed keywords

FLUOXETINE; PLACEBO; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; GENERAL PRACTICE; HEADACHE; HUMAN; INFLUENZA; INTERVIEW; MAJOR CLINICAL STUDY; NAUSEA; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SLEEP; SOMNOLENCE; SWEATING; VERTIGO; VOMITING; XEROSTOMIA;

EID: 0031007462     PISSN: 13552570     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Muth EA, Haskins JT, Moyer JA, Husbands GE, Nielsen ST and Sigg SB (1986) Antidepressant biochemical profile of the novel bicyclic compound Wy-45030, an ethyl cyclohexanol derivative. Biochemical Pharmacology, 35, 4493-4497.
2. Schweizer E, Weise C, Clary C, Fox I and Rickeis K (1991) Placebo-controlled trial of venlafaxine for the treatment of major depression. Journal of Clinical Psychopharmacology, 11, 233-236.
3. Mendels J, Johnston R, Mattes J and Riesenberg R (1993) Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacology Bulletin, 29, 169-174.
4. Khan A, Fabre LF and Rudolph R (1991) Venlafaxine in depressed outpatients. Psychopharmacology Bulletin, 27, 141-144.
5. Blanchard C, Hackett D, Danjou P and Nicholas T (1995) A randomised double-blind comparison of venlafaxine, imipramine and placebo in general practice patients with mild to moderate depression. European Neuropsychopharmacology, 5, 308.
6. Clerc GE, Ruimy P and Verdeau-Paillès J (1994) A double blind comparison of venlafaxine and fluoxetine in patients hospitalised for major depression and melancholia. International Clinical Psychopharmacology, 9, 139-143.
7. Guelfi JD, White C, Hackett D, Guichoux JY and Magni G (1995) Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. Journal of Clinical Psychiatry, 56, 450-458.
8. Danjou P and Hackett D (1995) Safety and tolerance profile of venlafaxine. International Clinical Psychopharmacology, 10(Suppl 2), 15-20.
9. Altamura AC, Montgomery SA and Wemicke JF (1988) The evidence for 20 mg a day of fluoxetine as the optimal dose in the treatment of depression. British Journal of Psychiatry, 153, 109-112.
10. Beasley CM, Bodsworth JC and Wernicke JF (1990) Fluoxetine: relationships among dose, response, adverse effects, and plasma concentrations in the treatment of depression. Psychopharmacology Bulletin, 26, 18-24.
11. Montgomery SA and Asberg M (1979) A new depression scale designed to be sensitive to change. British Journal of Psychiatry, 134, 382-389.
12. Hamilton M (1960) A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 56-62.
13. Guy W (1976) ECDEU Assessment Manual for Psychopharmacology, revised. DHEW publication no. (ADM)76-338. National Institutes of Mental Health, Rockville, MD.
14. Zigmond AS and Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatrica Scandanavica, 67, 361-370.
15. Paykel ES (1985) The clinical interview for depression. Development, reliability, and validity. Journal of Affective Disorders, 9, 85-96.
16. Wheatley D (1993) Sleep patterns in anxiety and depression associated with stress. Stress Medicine, 9, 127-129.
17. Dierick M, Ravizza L, Realini R and Martin A (1996) A double blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Progress in Neuropsychopharmacology and Biological Psychiatry, 20, 57-71.
18. Preskorn SH and Burke M (1992) Somatic therapy for major depressive disorder: selection of an antidepressant. Journal of Clinical Psychiatry, 53, 5-18.
19. Lecable P, Letzeiter J-M, Lichtblau E, Prak H, De Ruiter F, Burers Y and Hackett D (1995) An open-label study of the clinical acceptability of venlafaxine for depression. Primary Care Psychiatry, 1, 119-125.